Decreased frontal choline and neuropsychological performance in preclinical Huntington disease

Objectives: To study metabolic brain changes in preclinical carriers of Huntington disease (PreHD) using proton magnetic resonance spectroscopy (1H-MRS) and to examine their relationship to neuropsychological performance. Methods: Seventeen subjects with PreHD and 17 controls, matched for age and education, were studied. Frontal cortex and basal ganglia 1H-MRS, and a detailed neuropsychological battery, including visuomotor integration and speed, and memory, frontal, and visuospatial tests were performed. Statistical analysis included Student t-test and Pearson correlations (significance p < 0.05). Results: Frontal choline-containing compounds (CHO) were decreased in PreHD [t (32) = −2.834, p = 0.008]. Subjects with PreHD performed worse than controls in the 15-Objects test [t (32) = 4.077, p = 0.000], Luria motor alternances [t (32) = −2.094, p = 0.044], and Symbol Digit tests [t (32) = −2.136, p = 0.040]. Decreased frontal CHO in PreHD correlated to slowing in visuomotor tasks (the 15-Objects test: r = −0.60, p = 0.000, and the Symbol Digit: r = 0.37, p = 0.047). Conclusion: As choline-containing compounds relate to membrane turnover, membrane dysfunction antedating neuronal death is suggested to occur in the frontal cortex in preclinical carriers of Huntington disease. This dysfunction may be responsible for some of the neuropsychological deficits observed.

[1]  R. Prost,et al.  Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease , 2005, Brain Research.

[2]  Jan Aasly,et al.  Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: Indication of glial energy impairment in Huntington chorea, but not Parkinson disease , 2000, Journal of neuroscience research.

[3]  M. Chesselet,et al.  The use of transgenic and knock-in mice to study Huntington’s disease , 2003, Cytogenetic and Genome Research.

[4]  I. T. Draper,et al.  LURIA'S NEUROPSYCHOLOGICAL INVESTIGATION , 1976 .

[5]  R. Diamond,et al.  Evidence of presymptomatic cognitive decline in Huntington's disease. , 1992, Journal of clinical and experimental neuropsychology.

[6]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[7]  A. Ludolph,et al.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[8]  R. Yee,et al.  Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington’s disease , 2003, Vision Research.

[9]  E. Siemers,et al.  Subtle changes among presymptomatic carriers of the Huntington's disease gene , 2000, Journal of neurology, neurosurgery, and psychiatry.

[10]  J C Christian,et al.  Motor changes in presymptomatic Huntington disease gene carriers. , 1996, Archives of neurology.

[11]  J. Bradshaw,et al.  The effect of Huntington's disease and Gilles de la Tourette's syndrome on the ability to hold and shift attention , 1996, Neuropsychologia.

[12]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[13]  R H Myers,et al.  Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.

[14]  A. Jennekens‐Schinkel,et al.  Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. , 1997, Archives of neurology.

[15]  A. Benton,et al.  Visuospatial judgment. A clinical test. , 1978, Archives of neurology.

[16]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[17]  Jia Newcombe,et al.  High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions , 1995, Journal of neurochemistry.

[18]  M. Hayden,et al.  Presymptomatic neuropsychological impairment in Huntington's disease. , 1988, Archives of neurology.

[19]  D. Brooks,et al.  Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? , 1996, Movement disorders : official journal of the Movement Disorder Society.

[20]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[21]  Effects of unilateral posteroventral pallidotomy on ‘on–off’ cognitive fluctuations in Parkinson's disease , 2000, Neuropsychologia.

[22]  R. Reitan,et al.  Clinical neuropsychology: Current status and applications. , 1974 .

[23]  J. D. de Yébenes,et al.  Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.

[24]  F Lhermitte,et al.  Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment , 1989, Neurology.

[25]  T. Münte,et al.  Disturbance of “Extrinsic Alertness” in Huntington's Disease , 2002, Journal of clinical and experimental neuropsychology.

[26]  Ira Shoulson,et al.  Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals , 1990, Movement disorders : official journal of the Movement Disorder Society.

[27]  B. O’Donnell,et al.  Visual function in Huntington's disease patients and presymptomatic gene carriers , 2003, Movement disorders : official journal of the Movement Disorder Society.

[28]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[29]  D. Benson,et al.  Obsessions and compulsions in Gilles de la Tourette's syndrome , 1986, Neurology.

[30]  A Weindl,et al.  Central motor processing in Huntington's disease. A PET study. , 1997, Brain : a journal of neurology.

[31]  M. Lezak Neuropsychological assessment, 3rd ed. , 1995 .

[32]  D. Miller,et al.  Oligodendroglial gliomatosis cerebri: 1H-MRS suggests elevated glycine/inositol levels , 1999, Neuroradiology.

[33]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  S. Cerdán,et al.  Cerebral glucose metabolism and the glutamine cycle as detected by in vivo and in vitro 13 C NMR spectroscopy , 2004, Neurochemistry International.

[35]  A. Lundervold,et al.  Variability in cognitive function among persons at high genetic risk of Huntington's disease , 1995, Acta Neurologica Scandinavica.

[36]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[37]  E. Gómez-Tortosa,et al.  Visual processing disorders in patients with Huntington's disease and asymptomatic carriers , 1996, Journal of Neurology.

[38]  E. Siemers,et al.  Cognitive scores in carriers of huntington's disease gene compared to noncarriers , 1995, Annals of neurology.

[39]  J. Brandt,et al.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[40]  S. Folstein,et al.  Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease. , 1993, Archives of neurology.

[41]  T. Robbins,et al.  The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. , 1998, Brain : a journal of neurology.